Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CTS-AMI
NCT03792035Phase 4Unknown
- Sponsor
- National Center for Cardiovascular Disease
- Start
- May 2019
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Tongxinluo in ST elevation myocardial infarction (STEMI) (2 arms), sponsored by National Center for Cardiovascular Disease. Primary endpoint: Major Adverse Cardiovascular and Cerebrovascular Events at 30 days. Status: unknown.
02
Drugs
Tongxinluo
03
Conditions
ST elevation myocardial infarction (STEMI)
Beyond the preview
Go deeper on NCT03792035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03792035.